Neuro-protective Effect of Acetyl-11-keto-β-boswellic Acid in a Rat Model of Scopolamine-induced Cholinergic Dysfunction-Reference-Cited by-同舟云学术

Neuro-protective Effect of Acetyl-11-keto-β-boswellic Acid in a Rat Model of Scopolamine-induced Cholinergic Dysfunction

Published:2024-01 Issue:2 Volume:30 Page:140-150
ISSN:1381-6128
Container-title:Current Pharmaceutical Design
language:en
Short-container-title:CPD

Author:

Assaran Amir Hossein¹²,Hosseini Mahmoud¹²³⁴,Shirazinia Matin⁴,Eshaghi Ghalibaf Mohammad Hosein³,Beheshti Farimah⁵⁶,Mobasheri Leila⁷,Mirzavi Farshad⁸,Rajabian Arezoo⁴⁹

Affiliation:

1. Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

2. Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3. Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

4. Neuroscience Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

5. Neuroscience Research Center, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran

6. Department of Physiology, School of Medical Sciences, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran

7. Department of Pharmacology, Mashhad University of Medical Sciences, Mashhad, Iran

8. Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran

9. Department of Neuroscience, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Background:: Acetyl-11-keto-β-boswellic acid (AKBA) is a major component of the oleo-gum resin of B. serrata with multiple pharmacological activities. The objective of this study was to explore the underlying mechanisms of neuroprotective potential of AKBA against scopolamine-mediated cholinergic dysfunction and memory deficits in rats. Methods:: The rats received AKBA (2.5, 5, and 10 mg/kg, oral) for 21 days. In the third week, scopolamine was administered 30 min before the Morris water maze and passive avoidance tests. In order to perform biochemical assessments, the hippocampus and prefrontal cortex were extracted from the rats euthanized under deep anesthesia. Results:: In the MWM test, treatment with AKBA (5 and 10 mg/kg) decreased the latency and distance to find the platform. Moreover, in the PA test, AKBA remarkably increased latency to darkness and stayed time in lightness while decreasing the frequency of entry and time in the darkness. According to the biochemical assessments, AKBA decreased acetylcholinesterase activity and malondialdehyde levels while increasing antioxidant enzymes and total thiol content. Furthermore, AKBA administration restored the hippocampal mRNA and protein levels of brain-derived neurotrophic factor (BDNF) and mRNA expression of B-cell lymphoma (Bcl)- 2 and Bcl-2- associated X genes in brain tissue of scopolamine-injured rats. Conclusion:: The results suggested the effectiveness of AKBA in preventing learning and memory dysfunction induced by scopolamine. Accordingly, these protective effects might be produced by modulating BDNF, cholinergic system function, oxidative stress, and apoptotic markers.

Funder

Mashhad University of Medical Sciences

Publisher

Bentham Science Publishers Ltd.

Reference37 articles.

1. Nichols E.; Szoeke C.E.I.; Vollset S.E.; Abbasi N.; Abd-Allah F.; Abdela J.; Aichour M.T.E.; Akinyemi R.O.; Alahdab F.; Asgedom S.W.; Awasthi A.; Barker-Collo S.L.; Baune B.T.; Béjot Y.; Belachew A.B.; Bennett D.A.; Biadgo B.; Bijani A.; Bin Sayeed M.S.; Brayne C.; Carpenter D.O.; Carvalho F.; Catalá-López F.; Cerin E.; Choi J-Y.J.; Dang A.K.; Degefa M.G.; Djalalinia S.; Dubey M.; Duken E.E.; Edvardsson D.; Endres M.; Eskandarieh S.; Faro A.; Farzadfar F.; Fereshtehnejad S-M.; Fernandes E.; Filip I.; Fischer F.; Gebre A.K.; Geremew D.; Ghasemi-Kasman M.; Gnedovskaya E.V.; Gupta R.; Hachinski V.; Hagos T.B.; Hamidi S.; Hankey G.J.; Haro J.M.; Hay S.I.; Irvani S.S.N.; Jha R.P.; Jonas J.B.; Kalani R.; Karch A.; Kasaeian A.; Khader Y.S.; Khalil I.A.; Khan E.A.; Khanna T.; Khoja T.A.M.; Khubchandani J.; Kisa A.; Kissimova-Skarbek K.; Kivimäki M.; Koyanagi A.; Krohn K.J.; Logroscino G.; Lorkowski S.; Majdan M.; Malekzadeh R.; März W.; Massano J.; Mengistu G.; Meretoja A.; Mohammadi M.; Mohammadi-Khanaposhtani M.; Mokdad A.H.; Mondello S.; Moradi G.; Nagel G.; Naghavi M.; Naik G.; Nguyen L.H.; Nguyen T.H.; Nirayo Y.L.; Nixon M.R.; Ofori-Asenso R.; Ogbo F.A.; Olagunju A.T.; Owolabi M.O.; Panda-Jonas S.; Passos V.M.A.; Pereira D.M.; Pinilla-Monsalve G.D.; Piradov M.A.; Pond C.D.; Poustchi H.; Qorbani M.; Radfar A.; Reiner R.C.; Robinson S.R.; Roshandel G.; Rostami A.; Russ T.C.; Sachdev P.S.; Safari H.; Safiri S.; Sahathevan R.; Salimi Y.; Satpathy M.; Sawhney M.; Saylan M.; Sepanlou S.G.; Shafieesabet A.; Shaikh M.A.; Sahraian M.A.; Shigematsu M.; Shiri R.; Shiue I.; Silva J.P.; Smith M.; Sobhani S.; Stein D.J.; Tabarés-Seisdedos R.; Tovani-Palone M.R.; Tran B.X.; Tran T.T.; Tsegay A.T.; Ullah I.; Venketasubramanian N.; Vlassov V.; Wang Y-P.; Weiss J.; Westerman R.; Wijeratne T.; Wyper G.M.A.; Yano Y.; Yimer E.M.; Yonemoto N.; Yousefifard M.; Zaidi Z.; Zare Z.; Vos T.; Feigin V.L.; Murray C.J.L.; Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019,18(1),88-106

2. Tiwari S.; Atluri V.; Kaushik A.; Yndart A.; Nair M.; Alzheimer’s disease: Pathogenesis, diagnostics, and therapeutics. Int J Nanomed 2019,14,5541-5554

3. Mecocci P.; Boccardi V.; Cecchetti R.; Bastiani P.; Scamosci M.; Ruggiero C.; Baroni M.; A long journey into aging, brain aging, and Alzheimer’s disease following the oxidative stress tracks. J Alzheimers Dis 2018,62(3),1319-1335

4. Hassan N.A.; Alshamari A.K.; Hassan A.A.; Elharrif M.G.; Alhajri A.M.; Sattam M.; Khattab R.R.; Advances on therapeutic strategies for Alzheimer’s disease: From medicinal plant to nanotechnology. Molecules 2022,27(15),4839

5. Muhammad T.; Ali T.; Ikram M.; Khan A.; Alam S.I.; Kim M.O.; Melatonin rescue oxidative stress-mediated neuroinflammation/neurodegeneration and memory impairment in scopolamine-induced amnesia mice model. J Neuroimmune Pharmacol 2019,14(2),278-294